Frailty assessment in older transplant candidates

Transplantmedium

A 70-year-old man on in-center hemodialysis for 1 year requests kidney transplant evaluation. History includes ANCA vasculitis unsuccessfully treated with cyclophosphamide and Gleason 7 prostate cancer treated with radiation 8 years ago, in remission. Screening colonoscopy 4 years ago was normal. He has no extrarenal vasculitis symptoms. He reports exhaustion after dialysis and a 7-kg unintentional weight loss over the past year, and he leaves home only for dialysis. Grip strength is symmetric at 3/5. PSA is <0.1 ng/mL and ESR 4 mm/h. What is the most appropriate next step in his pretransplant evaluation?

  1. A.Colonoscopy
  2. B.Timed 15-foot walking testCorrect
  3. C.ANCA serology
  4. D.Urologic oncology referral

Explanation

The most appropriate next step is a timed 15-foot walking test as part of a frailty assessment. This 70-year-old man has several features of the frailty phenotype described by Fried: unintentional loss of 7 kg in a year, exhaustion, low physical activity (he leaves home only for dialysis), and weak grip strength. Slow gait speed, measured by the time to walk 15 feet, is the remaining component; three or more of five criteria define frailty. Frailty is common in dialysis patients, affects about one in five kidney transplant candidates, and independently predicts delayed graft function, longer hospitalization, early readmission, intolerance of immunosuppression, mortality on the waitlist, and death after transplantation. The KDIGO 2020 guideline on the evaluation of transplant candidates recommends assessing frailty in all candidates, using an objective tool such as the Fried frailty phenotype or the Short Physical Performance Battery. Identifying frailty does not automatically exclude transplantation: it supports shared decision-making, targeted prehabilitation, and nutritional intervention, and frailty can improve after successful transplantation. In this patient, completing the gait-speed measurement quantifies the risk most directly. ANCA serology is not required to decide candidacy. KDIGO recommends that patients with ANCA vasculitis be in clinical remission for at least 6 months before transplantation, and he has no extrarenal symptoms and a normal ESR. A persistently positive ANCA alone does not delay transplantation. Urologic oncology referral is unnecessary. His prostate cancer was treated 8 years ago, and an undetectable PSA indicates remission well beyond the waiting periods recommended for intermediate-risk disease. Colonoscopy was normal 4 years ago, and in an average-risk candidate, screening follows general population intervals, usually 10 years after a normal study.

Why each option

A.
A normal colonoscopy 4 years ago in an average-risk candidate means screening is not due until about 10 years after that study.
B.
Correct. Weight loss, exhaustion, low activity, and weak grip already meet frailty criteria; gait speed completes the Fried phenotype, which KDIGO recommends assessing in candidates.
C.
KDIGO requires clinical remission for 6 months rather than negative ANCA; with no extrarenal symptoms and ESR 4 mm/h, serology would not change candidacy.
D.
Prostate cancer treated 8 years ago with undetectable PSA is in durable remission beyond recommended waiting times, so oncology referral is unnecessary.

Reference: Chadban SJ, Transplantation 2020 (KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation); McAdams-DeMarco MA, Am J Transplant 2015 (frailty and kidney transplant outcomes)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Transplant questions

Browse other topics